Lombard Odier Asset Management USA Corp Acquires Shares of 20,567 Celldex Therapeutics, Inc. $CLDX

Lombard Odier Asset Management USA Corp bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 20,567 shares of the biopharmaceutical company’s stock, valued at approximately $419,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CLDX. Bollard Group LLC purchased a new position in Celldex Therapeutics in the second quarter valued at about $399,000. Jump Financial LLC raised its position in shares of Celldex Therapeutics by 53.3% in the 2nd quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock valued at $600,000 after purchasing an additional 10,255 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Celldex Therapeutics by 19.9% during the 2nd quarter. Invesco Ltd. now owns 62,886 shares of the biopharmaceutical company’s stock valued at $1,280,000 after buying an additional 10,443 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Celldex Therapeutics during the 2nd quarter valued at approximately $238,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Celldex Therapeutics during the second quarter worth approximately $347,000.

Insider Buying and Selling at Celldex Therapeutics

In related news, insider Richard M. Wright sold 49,298 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the sale, the insider owned 20,833 shares of the company’s stock, valued at approximately $499,992. This trade represents a 70.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.40% of the company’s stock.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $28.09 on Wednesday. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $30.50. The company has a 50-day simple moving average of $26.23 and a 200-day simple moving average of $23.72. The firm has a market capitalization of $1.87 billion, a PE ratio of -8.31 and a beta of 1.13.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. Equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CLDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Wells Fargo & Company cut their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 20th. Mizuho initiated coverage on Celldex Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 price target for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.